Orchestra BioMed Holdings, Inc. (OBIO) — Stock Score Summary

Orchestra BioMed Holdings, Inc. (OBIO) has a MoatMap StockRank of 25/100 based on Quality (31/100), Value (35/100), and Momentum (45/100) factor scores. The current signal is SELL. Orchestra BioMed is a clinical-stage medical device developer. It is pre-revenue, highly speculative, and relies entirely on binary clinical trial outcomes and regulatory approvals.

Orchestra BioMed Holdings, Inc. is a medical device company focused on developing disruptive therapies for heart failure and hypertension, with its lead product, BackBeat Cardiac Neuromodulation Therapy (CNT), targeting improved outcomes for HFpEF patients. Its competitive moat lies in its proprietary, patented technology addressing significant unmet medical needs in large patient populations, potentially establishing a new standard of care. Orchestra BioMed is a clinical-stage company leveraging strategic partnerships with major medical device firms to validate and commercialize its innovative solutions.

Key Financial Metrics

Price$4.03
Market Cap$238M
P/E (Forward)-2.74
Price/Book4.25
Return on Equity-161.1%
Return on Invested Capital-52.5%
Debt/Equity31.10
Gross Margin99.5%
Operating Margin-20069.1%
Revenue Growth-87.3%
Free Cash Flow$-26M

Orchestra BioMed Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Orchestra BioMed Holdings, Inc.’s (OBIO) StockRank?
MoatMap’s StockRank for Orchestra BioMed Holdings, Inc. (OBIO) is 25/100, with a Sell signal. It is a composite of Quality (31), Value (35), and Momentum (45) factor ranks across MoatMap’s 19,000+ stock universe.
Does Orchestra BioMed Holdings, Inc. have an economic moat?
Orchestra BioMed Holdings, Inc. (OBIO) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Orchestra BioMed Holdings, Inc. a buy, hold, or sell?
MoatMap’s current signal for Orchestra BioMed Holdings, Inc. (OBIO) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Orchestra BioMed Holdings, Inc. in?
Orchestra BioMed Holdings, Inc. (OBIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksOBIO deep dive reportAI ChampionsHow we score stocksSense-check another stock